Ensure Long-Acting Beta-Agonists Aren't Used Alone for Asthma

Labeling changes will bring up questions about the role of long-acting beta-agonists (LABAs) for asthma.

We've heard about early studies that suggest using a LABA withOUT an inhaled corticosteroid (ICS) increases the risk of asthma death.

This led to FDA's boxed warning in 2003 to stop LABAs once asthma is controlled...and required manufacturers to study the safety of LABAs in combo with inhaled steroids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote